BioInvent International The shareholders of BioInvent International AB, Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 27 April 2023 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.
Notice to Annual General Meeting in BioInvent International AB – March 27, 2023 Read More »
Incyte announced that the Japanese Ministry of Health, Labour and Welfare has approved Pemazyre®, a selective fibroblast growth factor receptor inhibitor, for the treatment of myeloid/lymphoid neoplasms with FGFR1 fusion.
Ionis Pharmaceuticals, Inc. announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy, a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.
Everest Medicines announced that it has received full upfront payment of $280 million from Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc., for the transaction around Trodelvy® rights in certain Asia territories.
Short-term safety was confirmed. Efficacy including visual acuity and corneal thickness is improving.
Aadi Bioscience, Inc. announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.
ImmunoGen, Inc. announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the
Hoffmann-La Roche Limited announced that on March 24, 2023 Health Canada authorized COLUMVI® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma, who have received two or more lines of systemic therapy and are ineligible to receive
Relmada Therapeutics announced it would make key changes to its clinical evaluation of REL-1017 as a possible add-on treatment for major depressive disorder.
Relmada Looks to Rebound with New Protocol After Two Phase III Flops Read More »
The FDA is expected to make decisions on Emergent BioSolutions’ sNDA for OTC Narcan and Roche’s Polivy in frontline DLBCL.
